Cisapride disposition in neonates and infants
Kearns, G.L.; Robinson, P.; Adcock, K.; Wilson Costello, D.; Knight, G.; Zhou, H.H.; Ward, R.; Van Den Anker, J.; Ppru Network
Clinical Pharmacology and Therapeutics 69(2): P31
2001
ISSN/ISBN: 0009-9236 Accession: 034583243
Full Text Article emailed within 1 workday: $29.90
Related References
Kearns, G.L.; Robinson, P.K.; Wilson, J.T.; Wilson-Costello, D.; Knight, G.R.; Ward, R.M.; van den Anker, J.N. 2003: Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny Clinical Pharmacology and Therapeutics 74(4): 312-325Lupoglazoff, J.M.; Bedu, A.; Faure, C.; Denjoy, I.; Casasoprana, A.; Cezard, J.P.; Aujard, Y. 1997: Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson - Long QT interval under cisapride in neonates and infants Journees Europeennes de la Societe Francaise de Cardiologie 4(6): 509-514
Zamora, S.A.; Jaeggi, E.; Friedli, B.; Belli, D.C. 2001: 24-Hour electrocardiogram before and during cisapride in neonates and infants JPGN Journal of Pediatric Gastroenterology and Nutrition 32(3): 380
Lupoglazoff, J.M.; Bedu, A.; Faure, C.; Denjoy, I.; Casasoprana, A.; Cézard, J.P.; Aujard, Y. 1997: Long QT syndrome under cisapride in neonates and infants Archives de Pediatrie: Organe Officiel de la Societe Francaise de Pediatrie 4(6): 509-514
Zamora, S.A.; Belli, D.C.; Friedli, B.; Jaeggi, E. 2004: 24-hour electrocardiogram before and during cisapride treatment in neonates and infants Biology of the Neonate 85(4): 229-236
Lander, A.; Desai, A. 1998: The risks and benefits of cisapride in premature neonates, infants, and children Archives of Disease in Childhood 79(6): 469-470
Marcadis, M.L.; Kraus, D.M.; Chow Tung, E.; Young, S.L.; Mcculloch, K.M.; Fischer, J.H. 1991: Effects of maturation on gentamicin disposition in neonates and infants Pharmacotherapy 11(3): 269
Kearns, G.L.; Jungbluth, G.L.; Abdel-Rahman, S.M.; Hopkins, N.K.; Welshman, I.R.; Grzebyk, R.P.; Bruss, J.B.; Van Den Anker, J.N. 2003: Impact of ontogeny on linezolid disposition in neonates and infants Clinical Pharmacology and Therapeutics 74(5): 413-422
Reed, M.D.; Gooch, W.M.; Minton, S.D.; Tanaka-Kido, J.; Santos, J.I.; Yamashita, T.S.; Blumer, J.L. 1991: Ceftizoxime disposition in neonates and infants during the first six months of life Dicp: the Annals of PharmacoTherapy 25(4): 344-347
Levin, R.H. 1991: Principles of drug disposition and therapy in neonates infants and children Rudolph, A M (Ed ) Rudolph's Pediatrics, 19th Edition Xlii+2111p Appleton And Lange: East Norwalk, Connecticut, Usa; Prentice-Hall International (Uk) Ltd : London, England, Uk Illus Maps 859-862
Jungbluth, G.L.; Welshman, I.R.; Hopkins, N.K.; Bruss, J.B.; Wu, E.; Kearns, G.L. 2002: Impact of gestational and postnatal age on linezolid disposition in neonates and young infants Pediatric Research 51(4 Part 2): 465A
Galinkin, J.L.; Davis, P.J.; Szmuk, P.; Orr, R.; Krane, E.J.; Edwards, S.; Kurth, C.D.; Mcgowan, F.X.; Lynn, A.M.; Rabb, M.F.; Yaster, M.; Henson, L.G.; Blum, R.; Hechtman, D.; Maxwell, L. 2001: A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. II. Perioperative breathing patterns in neonates and infants with pyloric stenosis Anesth. Analg 93(6): 1387-1392
Galinkin, J.L.; Davis, P.J.; McGowan, F.X.; Lynn, A.M.; Rabb, M.F.; Yaster, M.; Henson, L.G.; Blum, R.; Hechtman, D.; Maxwell, L.; Szmuk, P.; Orr, R.; Krane, E.J.; Edwards, S.; Kurth, C.D. 2001: A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. II. Perioperative breathing patterns in neonates and infants with pyloric stenosis Anesthesia and Analgesia 93(6): 1387-92 Table of Contents
Davies, M.W. 2000: The use of cisapride in neonates Archives of Disease in Childhood. Fetal and Neonatal Edition 83(1): F75
Choo, E.F.; Venkatakrishnan, K.; Hatch, H.L.; Rahematpura, S. 2005: Disposition of cisapride appears to be influenced by P-glycoprotein in the mouse Clinical Pharmacology and Therapeutics 77(3): 225-226